Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's Lymphoma
2010
A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression
2005 StandoutNobel
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
2011 Standout
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
2008 StandoutNobel
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
2010 Standout
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
2011 Standout
Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography–Staged Treatment-Naive Patients With Hodgkin Lymphoma
2012
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
2015
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2011 Standout
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
2009 StandoutNobel
Cancer statistics, 2022
2022 Standout
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group
2008
Cancer statistics, 2023
2023 Standout
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Gastric cancer
2016 Standout
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2024
2024 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
Cancer Statistics, 2021
2021 Standout
Optimal chemotherapy for advanced gastric cancer: is there a global consensus?
2013
Novel radiolabeled antibody conjugates
2007
Myeloid-derived suppressor cells coming of age
2018 Standout
Post-remission therapy for acute myeloid leukemia
2014
Transforming Growth Factor-β Signaling in Immunity and Cancer
2019 Standout
Rituximab
2003
Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step
2009
Curcumin nanodisk-induced apoptosis in mantle cell lymphoma
2011
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
2012
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia
2002
Curcumin (diferuloylmethane) inhibits constitutive NF-κB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma
2005
Delivery technologies for cancer immunotherapy
2019 Standout
Detection of histone modifications at specific gene loci in single cells in histological sections
2013
Apoptosis in cancer: from pathogenesis to treatment
2011 Standout
Molecular characterization ofde novoPhiladelphia chromosome-positive acute myeloid leukemia
2012
Targeting apoptosis in cancer therapy
2020 Standout
Caspase Functions in Cell Death and Disease
2013 Standout
Toxicities of the Thrombopoietic Growth Factors
2010
Selectively functionalized cyclodextrins and their metal complexes
2009
18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging
2010
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
2012 Standout
Gastric cancer
2020 Standout
Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer
2007
Microtubules as a target for anticancer drugs
2004 Standout
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer
2011
Regulatory T cells in tumor immunity
2010 StandoutNobel
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
2004
Idelalisib: First Global Approval
2014
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
2021
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
2008
Curcumin: From ancient medicine to current clinical trials
2008 Standout
Chimeric antigen receptor T-cell therapies for lymphoma
2017
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper
2010
Peripheral T- cell lymphomas: diagnosis and management
2003
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
2008
Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia.
2009
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
2018
Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia
2009
Hodgkin lymphoma: 2018 update on diagnosis, risk‐stratification, and management
2018
Apoptosis: A Target for Anticancer Therapy
2018 Standout
Acute Myeloid Leukemia
2015 Standout
Interleukin‐21 (IL ‐21) synergizes with IL ‐2 to enhance T ‐cell receptor‐induced human T‐cell proliferation and counteracts IL ‐2/transforming growth factor‐β‐induced regulatory T‐cell development
2012
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
2006 Standout
The Tumor Lysis Syndrome
2011 Standout
Supramolecular Chirality in Self-Assembled Systems
2015 Standout
Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie
2007
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
2005 Standout
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
2009 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Chemotherapy for advanced gastric cancer
2017 Standout
Mechanisms of Plaque Formation and Rupture
2014 Standout
Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma
2006
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia
2013
Toward the potential cure of leukemias in the next decade
2018
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Chimeric Antigen Receptor Therapy
2018 Standout
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
Cytokines in Cancer Immunotherapy
2011
Vascular Smooth Muscle Cells in Atherosclerosis
2016 Standout
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?
2014
Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines
2008
Ibrutinib: A First in Class Covalent Inhibitor of Bruton's Tyrosine Kinase
2014
Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study
2005
Molecular targets of dietary agents for prevention and therapy of cancer
2006 Standout
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD
2014
The Essential Medicinal Chemistry of Curcumin
2017 Standout
Circulating myeloid‐derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up‐front with a risk‐adapted strategy
2014
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia
2005
Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy‐related leukemia
2015
Real-Time PCR Technology for Cancer Diagnostics
2002
Works of Mathias Rummel being referenced
Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study
2009
Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma—role of radioimmunotherapy
2006
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
2007
PTPIP51 is phosphorylated by Lyn and c-Src kinases lacking dephosphorylation by PTP1B in acute myeloid leukemia
2011
Bendamustine in the treatment of non-Hodgkin's lymphoma: Results and future perspectives
2002
Subclones with the t(9;22)/BCR‐ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations
2011
In vitro studies with bendamustine: Enhanced activity in combination with rituximab
2002
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Treatment of Aggressive, or Progressing Indolent Peripheral T- and NK-Cell Neoplasias by Combination of Fludarabine, Cyclophosphamide and Doxorubicine
2001
Altered Apoptosis Pathways in Mantle Cell Lymphoma
2003
Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel
2010
Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: A German multicenter phase II study
1999
Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma
2002
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL)
2008
Efficacy and Safety of a Single-Course of Yttrium-90 Ibritumomab Tiuxetan for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma after/not Appropriate for Autologous Stem Cell Transplantation - Final Analysis of a Phase II Trial of the European MCL Network.
2007
Fludarabine Versus Fludarabine Plus Epirubicin in the Treatment of Chronic Lymphocytic Leukemia - Final Results of a German Randomized Phase-III Study.
2005
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
2013
Bendamustine: Rebirth of an Old Drug
2009
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
2013
MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma.
2019
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
2010
Prognostic Impact of Minimal Residual Disease inCBFB-MYH11–Positive Acute Myeloid Leukemia
2010
Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma
2005
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
2002
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line Treatment of Patients with Indolent and Mantle Cell Lymphomas - First Interim Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).
2007
Phase II Trial of Biweekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin in Patients With Advanced Gastric Cancer
2004
Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.
2009